TrialPhase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
Trial details
- Registry ID
- NCT06435845
- Phase
- Phase 2
RLYB
Rallybio
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
1Trials in this database
7Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a AlloimmunizationNCT06435845 | Rallybio | Phase 2 | Terminated | 2025-10-01Actual |
Latest recorded trial changes
Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
NCT06435845 · Rallybio
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Number of Participants with treatment related adverse events as defined by CTCAE 5.0
Measure: Maternal exposure to RLYB212 as measured in serum
+ After
Measure: Number of Participants With Treatment Related Adverse Events as Defined by CTCAE 5.0 Measure: Maternal Exposure to RLYB212 as Measured in Serum
Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
NCT06435845 · Rallybio
Recruitment status changed
− Before
Completed
+ After
Terminated
Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
NCT06435845 · Rallybio
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
8 participants (planned)
+ After
1 participants (actual)
Recruitment status changed
− Before
Active not recruiting
+ After
Completed
Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization
NCT06435845 · Rallybio
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
May 2027
+ After
1 Oct 2025